Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 1

Sponsor Class

OTHER 8INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 5Nasopharyngeal Carcinoma 4Lung Neoplasms 4Triple Negative Breast Neoplasms 3Stomach Neoplasms 3Uterine Cervical Neoplasms 2Solid Tumor 2Sarcoma 2Respiratory Tract Diseases 2Lung Diseases 2Esophageal Neoplasms 2Carcinoma, Hepatocellular 2Carcinoma, Bronchogenic 2Bronchial Neoplasms 2Breast Neoplasms 2Advanced Solid Tumors 2Advanced Solid Tumor 2Thoracic Neoplasms 1Small Cell Lung Carcinoma 1Respiratory Tract Neoplasms 1Recurrence 1Pancreatic Neoplasms 1PD-L1 Positive Non-small Cell Lung Cancer 1Non-squamous Non-small-cell Lung Cancer 1Non-squamous Non-small Cell Lung Cancer 1Non Squamous Non Small Cell Lung Cancer 1Neoplasms by Site 1Neoplasm Metastasis 1Lymphoma, Extranodal NK-T-Cell 1Hodgkin Disease 1

Interventions

Gemcitabine 205130-nm albumin-bound paclitaxel 84Albumin-Bound Paclitaxel 57pembrolizumab 43Fluorouracil 41Leucovorin 34Oxaliplatin 33Capecitabine 25Nivolumab 22Irinotecan 19Bevacizumab 17Paclitaxel 16Cyclophosphamide 15Cetuximab 15Taxes 13Erlotinib Hydrochloride 13Drug Therapy 13Carboplatin 12irinotecan sucrosofate 11Injections 10Cisplatin 9fludarabine 8ALT-803 8spartalizumab 7olaparib 7avelumab 7Pemetrexed 7Docetaxel 7ruxolitinib 6TH 302 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Pancreatic Neoplasms × camrelizumab × Clear all
NCT06361888 2026-05-28

A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer

Hutchmed

Phase 2/3 Recruiting
502 enrolled
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡